May 24, 2022
Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer
Radiology
Background Data regarding 2-(3-{1-carboxy-5-[(6-[^(18)F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (^(18)F-DCFPyL) PET in primary staging of prostate cancer (PCa) are limited. Purpose To compare the performance of ^(18)F-DCFPyL PET/CT or PET/MRI (PET) with bone scan and CT with or without multiparametric MRI (hereafter, referred to as conventional imaging) in the initial staging of men with unfavorable intermediate or high-risk PCa and to assess treatment change after...